AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT04019288 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

12

Enrollment

OTHER

Sponsor class

Stopped PI Request

Conditions

Platinum-Resistant Fallopian Tube Carcinoma
Platinum-Resistant Ovarian Carcinoma
Platinum-Resistant Primary Peritoneal Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma
Refractory Fallopian Tube Carcinoma
Refractory Ovarian Carcinoma
Refractory Primary Peritoneal Carcinoma

Interventions

DRUG: Batiraxcept
BIOLOGICAL: Durvalumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]